Research guide · Published July 22, 2026 · Sources checked July 22, 2026
5-Amino-1MQ and NNMT inhibition: mechanism and model limits
5-Amino-1MQ—also written 5-amino-1-methylquinolinium—is an experimental small molecule rather than a peptide. Published studies use it as a membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT).
Short answer
5-Amino-1MQ is studied as an NNMT inhibitor. The cited work measures enzyme inhibition, metabolites, cultured-cell behavior, mouse-model endpoints, and rat pharmacokinetics. These models support a mechanistic research program, but they do not establish clinical effectiveness, safety, or equivalence of independently supplied material.
Evidence boundary: No cited human trial establishes a therapeutic effect, safety profile, weight-loss outcome, or general human-use profile for 5-Amino-1MQ. Catalog materials are supplied only for qualified in vitro laboratory research and are not for human or animal use.
Comparison at a glance
| Research question | What the selected studies measured | Evidence boundary |
|---|---|---|
| What is the molecular target? | NNMT activity and related methylation-pathway measurements | An enzyme target does not establish an organism-level outcome |
| What kind of molecule is 5-Amino-1MQ? | A synthetic quinolinium small molecule used as an experimental inhibitor | It should not be described as a peptide |
| What models were used? | Biochemical assays, cultured cells, diet-induced-obesity mice, muscle-injury mice, and rat PK | Results depend on species, tissue, route, and protocol |
| What does rat PK add? | A validated LC–MS/MS assay and plasma exposure measurements | Exposure measurements do not prove efficacy or long-term safety |
How to interpret the comparison
NNMT sits within nicotinamide and methyl-donor metabolism, so a change in NNMT activity can affect multiple downstream measurements. The observed result must still be attributed to the specific model and protocol rather than generalized from the target name.
The 2017 and 2019 studies are preclinical. The 2021 rat work improves bioanalytical understanding, but pharmacokinetics and a measurable plasma concentration are not clinical validation.
Primary sources
- Neelakantan et al., Scientific Reports (2017) — Biochemical characterization and diet-induced-obesity mouse experiments involving membrane-permeable NNMT inhibitors. DOI: 10.1038/s41598-017-15850-7
- Neelakantan et al., Biochemical Pharmacology (2019) — C2C12 cell and mouse muscle-injury experiments examining NNMT inhibition. DOI: 10.1016/j.bcp.2019.02.008
- Awosemo et al., Journal of Pharmaceutical and Biomedical Analysis (2021) — Validated LC–MS/MS method and pharmacokinetic measurements for 5-Amino-1MQ in rat plasma. DOI: 10.1016/j.jpba.2021.114255
Continue in the research library
Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.